Supporting the next generation of scientists developing new approaches to antimicrobial resistance. Antimicrobial resistance represents a major global health challenge and highlights the need to… Read More »Industrial PhD research at Telum Therapeutics advances the development of new antimicrobial proteins
A pioneering R&D project led by Telum Therapeutics, in collaboration with the Complutense University of Madrid (UCM) and the Carlos III Health Institute (ISCIII), has… Read More »Telum Therapeutics, Complutense University of Madrid and Carlos III Health Institute discover next-generation antimicrobials against vancomycin-resistant E. faecium
Telum is pleased to announce the filing of a new patent for Telum’s proprietary modular library cloning system. This patent represents a significant advancement in… Read More »Telum Bolsters APEXp Platform with ‘TelClo System’ Patent Filing
Navarra, Spain – January 24, 2025 – Telum Therapeutics, a global biotechnology company specializing in the development of engineered direct acting lytic proteins as novel antimicrobial… Read More »Telum Therapeutics Joins BEAM Alliance to Combat Antimicrobial Resistance
Pamplona, Spain – December 24, 2024– Telum Therapeutics, a leading biotechnology company specializing in drug discovery, is pleased to announce the filing of a new patent,… Read More »Telum Therapeutics Announces Filing of New Patent for Antimicrobial Peptides
In the age of antibiotic resistance, new strategies are needed to treat bacterial infections. In this scenario, bacteriophages, viruses able to infect and kill bacteria,… Read More »Mechanism linked to phage therapy resistance unraveled
Antimicrobial resistance (AMR) poses a significant threat to the health of all humankind, with potentially devastating economic consequences. In 2015, the World Health Organization (WHO)… Read More »Antimicrobial resistance is on the rise, warns a new report from the World Health
Organization
The concentrations of antibiotic residues found in wastewater and wastewater treatment plants of the WHO Western Pacific region (WPR) and the South-East Asia region (SEAR)… Read More »Antibiotic residues in water may pose a risk to human health
Pamplona, Spain, December 7th 2022.- Telum Therapeutics announced today that Mr. Daniel Couto has been designated to its Board of Directors as an independent director.… Read More »Telum Therapeutics appoints Daniel Couto as a new independent director
Founded in 1868, H.C. Wainwright & Co. is one of the US oldest and most trusted financial institutions. Committed to linking public and private growth… Read More »Telum Therapeutics presents at the H.C. Wainwright 1st Annual Investor Virtual
Conference on Bacteriophage
